Form 8-K - Current report:
SEC Accession No. 0001326190-25-000055
Filing Date
2025-11-06
Accepted
2025-11-06 07:04:53
Documents
14
Period of Report
2025-11-06
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.02: Results of Operations and Financial Condition
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K alt-20251106x8k.htm   iXBRL 8-K 47989
2 EX-10.1 alt-20251106xex10d1.htm EX-10.1 1055119
3 EX-99.1 alt-20251106xex99d1.htm EX-99.1 176620
4 GRAPHIC alt-20251106xex99d1002.jpg GRAPHIC 7092
  Complete submission text file 0001326190-25-000055.txt   1596573

Data Files

Seq Description Document Type Size
5 EX-101.SCH alt-20251106.xsd EX-101.SCH 24996
16 EXTRACTED XBRL INSTANCE DOCUMENT alt-20251106x8k_htm.xml XML 4868
Mailing Address 910 CLOPPER ROAD SUITE 201S GAITHERSBURG MD 20878
Business Address 910 CLOPPER ROAD SUITE 201S GAITHERSBURG MD 20878 2406541450
Altimmune, Inc. (Filer) CIK: 0001326190 (see all company filings)

EIN.: 202726770 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-32587 | Film No.: 251456091
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)